Gastroretentive delivery systems: A mini review

Drug Development and Industrial Pharmacy

Volumn 30, Issue 10, 2004, Pages 1019-1028

  Talukder, R ^a   Fassihi, R ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Bioadhesive; Drug delivery; Floating devices; High density system; Intragastric; Mucoadhesive; Proximal GI

Indexed keywords

ACETOHYDROXAMIC ACID; ALGINIC ACID; AMOXICILLIN; BICARBONATE; CARBOXYMETHYLCELLULOSE; CARRAGEENAN; CELLABURATE; CHITOSAN; CHONDROITIN SULFATE; COLESTYRAMINE; DEXTRAN; HEXADIMETHRINE BROMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; MACROGOL; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PECTIN; POLYACRYLIC ACID; POLYLYSINE; POVIDONE; PROTON PUMP INHIBITOR; TRIETHANOLAMINE;

DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GASTRORETENTIVE DELIVERY SYSTEM; HUMAN; NONHUMAN; SHORT SURVEY; STOMACH ABSORPTION; STOMACH EMPTYING; STOMACH LESION; STOMACH MOTILITY; STOMACH PH;

DRUG DELIVERY SYSTEMS; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 9644262439     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-200040239     Document Type: Short Survey

References (82)

1. Rouge, N.; Buri, P.; Doelker, E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int. J. Pharm. 1996, 136, 117-139.
2. Fell, J.T.; Whitehead, L.; Collet, H. Prolonged gastric retention using floating dosage forms. Pharm. Technol. 2000, 24 (3), 82-90.
3. Matharu, R.S.; Sanghavi, N.M. Novel drug delivery system for captopril. Drug Dev. Ind. Pharm. 1992, 18, 1567-1574.
4. Fell, J.T. Delivery systems for targeting to specific sites in the gastrointestinal tract. J. Pharm. Pharmacol. 1999, 51 (Suppl), 41.
5. Baumgartner, S.; Kristl, J.; Vrecer, F.; Vodopivec, P.; Zorko, B. Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int. J. Pharm. 2000, 795 (1-2), 125-135.
6. Deshpande, A.A.; Rhodes, C.T.; Shah, N.H.; Malick, A.W. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev. Ind. Pharm. 1996, 22 (6), 531-539.
7. Ateshkadi, A.; Lam, N.; Johnson, C.A. Clin. Pharm. 1993, 12, 34-48.
8. Chatterjee, A.; Yasmin, T.; Bagchi, D.; Stohs, S.J. The bactericidal effects of lactobacillus acidophilus, garcinol, and protykin compared to clarithromycin on Helicobacter Pylori. Mol. Cell. Biochem. 2003, 243 (1-2), 29-35.
9. Menon, A.; Wolfgang, A.; Ritschel, A.; Sakr, A. Development of and evaluation of a monolithic floating dosage form for furosemide. J. Pharm. Sci. 1994, 83, 239-245.
10. Rubinstein, A. Microbially controlled drug delivery to the colon. Biopharm. Drug Dispos. 1990, 77, 465-475.
11. Dressman, J.B.; Berardi, R.R.; Dermentzoglou, L.C.; Russell, T.L.; Schmaltz, S.P.; Barnett, J.L.; Jarvenpaa, K.M. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res. 1990, 7, 756-761.
12. Russell, T.L.; Berardi, R.R.; Barnett, J.L.; Dermentzoglou, L.C.; Jarvenpaa, K.M.; Schmaltz, S.P.; Dressman, J.B. Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women. Pharm. Res. 1993, 10 (2), 187-196.
13. Lui, C.Y.; Amidon, G.L.; Berardi, R.R.; Fleisher, D.; Youngberg, C.; Dressman, J.B. Comparison of gastrointestinal pH in dog and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci. 1986, 75, 271-274.
14. Mojaverian, P.; Chan, K.K.H. (a). Radiotelemetric determination of gastrointestinal pH, in vitro accuracy and in vivo reproducibility in man. Pharm. Res. 1988, 5, S-243.
15. Feldman, M.; Barnett, C. Dig. Dis. Sci. 1991, 36, 866-869.
16. Charman, W.N.; Porter, J.H.; Mithani, S.; Dressman, J.B. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 1997, 86 (3), 269-282.
17. Varis, K.; IHamaki, T.; Harkonen, M.; Samlof, I.M.; Siruala, M. Gastric morphology, function, and immunology in first-degree relatives of probands with pernicious anemia and controls. Scand. J. Gastroenterol. 1979, 14 (2), 129-139.
18. Holt, P.R.; Rosenberg, H.; Russell, R.M. Causes and consequences of hypochlorhydria in elderly. Dig. Dis. Sci. 1989, 34 (6), 933-937.
19. Lake-Bakaar, G.; Quadros, E.; Beidas, S.; Elaskr, M.; Tom, W.; Wilson, D.; Dinscoy, H.P.; Cohen, P.; Straus, E.W. Ann. Intern. Med. 1988, 772, 502-504.
20. Benn, A.; Cooke, W.T. Intraluminal pH of duodenum and jejunum in fasting subjects with normal and abnormal gastric or pancreatic function. Scand. J. Gastroenterol. 1971, 6, 313-317.
21. Mojaverian, P.; Chan, K.K.H.; Desai, A.; John, V. Gatrointestinal transit of a solid indigestible capsule as measured by radiotelemetry and dual gama scintigraphy. Pharm. Res. 1989, 6, 719-724.
22. Evans, D.F.; Pye, G.; Bramley, R.; Clark, A.G.; Dyson, T.J.; Hardcastle, J.D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988, 29, 1035-1041.
23. Fell, J.T. Targeting of drugs and delivery systems to specific sites in the gastrointestinal tract. J. Anat. 1996, 189, 517-519.
24. Sarna, S.K. Cyclic motor activity, migrating motor complex. Gastroenterology 1985, 89, 894-913.
25. Rubinstein, A.; Li, V.H.K.; Robinson, J.R. Gastrointestinal-physiological variables affecting performance of oral sustained release dosage forms. In Oral Sustained Release Formulations: Design and Evaluation; Yacobi, A., Halperin, W.E., Eds.; New York, Pergamon, 1988, (Chapter 6).
26. Schemann, M.; Ehlein, H.J. Mechanical characterstics of phase II and phase II of the interdigestive migrating motor complex in dogs. Gastroenterology 1986, 91, 117-123.
27. Wilding, I.R.; Coupe, A.J.; Davis, S.S. The role of γ-scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. 1991, 7, 87-117.
28. Shargel, L.; Yu, A. Applied Biopharmaceutics and Pharmacokinetics, 4th Ed.; Appleton and Lange: Philadelphia, 1999.
29. Hofmann, A.F.; Pressman, J.H.; Code, C.F.; Witztum, K.F. Controlled entry of orally administered drugs: physiological considerations. Drug Dev. Ind. Pharm. 1983, 9 (7), 1077-1109.
30. Kutchai, H.C. The gastrointestinal system. In Principles of Physiology; 2nd Ed.; Berne, R.M., Levy, M.N., Eds.; Mosby Year Book: St. Louis, MO, 1996; 652-686.
31. Haus, L.C.; Fell, J.T. Effect of stress on the gastric emptying of capsules. J. Clin. Hosp. Pharm. 1984, 9, 249-251.
32. Reddy, S.M.; Sinha, V.R.; Reddy, D.S. Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs. Drugs Today 1999, 35 (7), 537-580.
33. Ollerenshaw, K.J.; Norman, S.; Wilson, G.G.; Hardy, J.G. Exercise and small intestinal transit. Nucl. Med. Commun. 1987, 8, 105-110.
34. Mojaverian, P.; Vlasses, P.H.; Kellner, P.E.; Rocci, M.L. Effects of gender, posture, and age on gastric residence time of an indigestible solid: Pharmaceutical considerations. Pharm. Res. 1988, 5 (10), 639-643.
35. Kinget, R.; Kalala, W.; Vervoort, L.; Mooter, G.V. Colonic drug targeting. J. Drug Target. 1998,6 (2), 129-149.
36. Davis, S.S.; Khosla, R.; Wilson, G.G.; Washington, N. The gastrointestinal transit of a controlled release pellet formulation of tiaprofenic acid. Int. J. Pharm. 1987, 35, 253-258.
37. Park, H.M.; Chernish, J.M.; Rosenbeck, B.D.; Brunelle, R.L.; Hargrove, B.; Wellman, H.N. Gastric emptying of enteric coated tablets. Dig. Dis. Sci. 1984, 29, 207-212.
38. Coupe, A.J.; Davis, S.S.; Wilding, I.R. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm. Res. 1991, 8 (3), 360-364.
39. Khosla, R.; Feely, L.C.; Davis, S.S. Gastrointestinal transit of non-disintegrating tablets in fed subjects. Int. J. Pharm. 1989, 53, 107-117.
40. Davis, S.S.; Hardy, G.J.; Taylor, M.J.; Whalley, D.R.; Wilson, G.G. The effect of food on the gastrointestinal transit of pellets and an osmotic device (Osmet). Int. J. Pharm. 1984, 21, 331-340.
41. Hunter, E.; Fell, J.T.; Sharma, H. The gastric emptying of pellets contained in hard gelatin capsules. Drug Dev. Ind. Pharm. 1982, 8, 751-757.
42. Marvola, M.; Aito, H.; Ponto, P.; Kanniksoki, A.; Nykanen, S.; Kokkonen, P. Gastrointestinal transit and concomitant absorption of verapamil from single unit sustained released tablet. Drug Dev. Ind. Pharm. 1987, 13, 1593-1609.
43. Ch'ng, H.S.; Park, H.; Kelly, P.; Robinson, J.R. Bioadhesive polymers as platforms for oral controlled drug delivery. II. Synthesis and evaluation of some swelling, water insoluble polymers. J. Pharm. Sci. 1985, 74 (4), 399-405.
44. Longer, M.A.; Ch'ng, H.S.; Robinson, J.R. Bioadhesive polymers as platforms for oral controlled drug delivery. III. Oral delivery of Chlorothiazide using bioadhesive polymers. J. Phar. Sci. 1985, 74 (4), 406-411.
45. Park, K.; Robinson, J. Bioadhesive polymers as platform for oral-controlled drug delivery: method to study bioadhesion. Int. J. Pharm. 1984, 19 (1), 107-127.
46. Smart, J.D.; Kellaway, L.W. Pharmaceutical factors influencing the rate of gastrointestinal transit in an animal model. Intl. J. Pharm. 1989, 53, 79-83.
47. Sakkinen, M.; Linna, A.; Ojala, S.; Jurjenson, H.; Veski, P.; Marvola, M. In vivo evaluation of matrix granules containing microcrystalline chitosan as a gel forming excipient. Int. J. Pharm. 2003, 250 (1), 227-237.
48. De la torro, P.M.; Torrado, S.; Torrado, S. Interpolymer complexes of poly(acrylic acid) and chitosan: influence of the ionic hydrogel-forming medium. Biomaterials 2003, 24 (8), 1459-1468.
49. Preda, M.; Leucuta, S.E. Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization. J. Microencapsul 2003, 20 (6), 777-789.
50. Kikendall, J.W.; Friedman, A.C.; Oyewole, M.A.; Fleischer, D.; Johnson, L.F. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig. Dis. Sci. 1983, 28, 174-182.
51. Agyilirah, G.A.; Green, M.; duCret, R. Evaluation of gastric retention properties of a cross-linked polymer-coated tablet versus those of a nondisintegrating tablet. Int. J. Pharm. 1991, 75, 241-247.
52. Bechgaard, H.; Baggesen, S. Propoxyphene and norpropoxyphene: influence of type of controlled release formulation on intra-and inter-subject variations. J. Pharm. Sci. 1980, 69 (11), 1327-1330.
53. Devereux, J.E.; Newton, J.M.; Short, M.B. The influence of density on the gastrointestinal transit of pellets. J. Pharm. Pharmacol. 1990, 42, 500-501.
54. Clarke, G.M.; Newton, J.M.; Short, M.B. Comparative gastrointestinal transit of pellet systems of varying desnsity. Int. J. Pharm. 1995, 114 (1), 1-11.
55. Davis, S.S.; Stockwell, A.F.; Taylor, M.J.; Hardy, J.G.; Whalley, D.R.; Wilson, G.G.; Bechgaard, H.F.N. Christensen, the effect of density on the gastric emptying of single-and multiple-unit dosage forms. Pharm. Res. 1986, 3 (4), 208.
56. Sugito, K.; Ogata, H.; Goto, H.; Noguchi, M.; Kogure, T.; Takano, M.; Maruyama, Y.; Sasaki, Y. Gastrointestinal transit of non-disintegrating silid formulations in humans. Int. J. Pharm. 1990, 60, 89-97.
57. Seth, P.R.; Tossounian, J.L. Sustained Release Pharmaceutical Capsules. US Patent 4,126,672, November 1978.
58. Seth, P.R.; Tossounian, J.L. Novel Sustained Release Tablet Formulations. US Patent 4,167,558, September 1979.
59. Watanabe, S. Kayano, M. Ishino, Y. Miyao, K. Solid Therapeutic Preparation Remaining in the Stomach. US Patent 3,976,764, August 1976.
60. Harrigan, R.M. Drug Delivery Device for Preventing Contact of Undissoved Drug with the Stomach Lining. US Patent 4,055,178, October 1977.
61. Michaels, A.S.; Bashaw, J.D.; Zaffaroni, A. Gastro-Inflatable Drug Delivery Device. US Patent 3,901,232, 1975.
62. Stockwell, A.F.; Davis, S.S.; Walker, S.E. In vitro evaluation of alginate gel systems as sustained release drug delivery systems. J. Control. Release 1986, 3, 167-175.
63. Ichikawa, M.; Watanabe, S.; Miyake, Y. A new multiple-unit oral floating dosage system. I. Preparation and in vitro evaluation of floating and sustained release characteristics. J. Pharm. Sci. 1991, 80, 1062-1066.
64. Baumgartner, S.; Kristl, J.; Vrecer, F.; Vodopivec, P.; Zorko, B. Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int. J. Pharm. 2000, 795 (1-2), 125-135.
65. Oth, M.; Franz, M.; Timmermans, J.; Moes, A. The bilayer floating capsule: a stomach-directed drug delivery system for Misoprostol. Pharm. Res. 1992, 9 (3), 298-302.
66. Young, L.; Fassihi, R. Zero-order release kinetics from a self correctable floatable asymmetric configuration drug delivery system. J. Pharm. Sci. 1996, 85, 170-173.
67. Kawashima, Y.; Niwa, T.; Takechi, H.; Hino, T.; Itoth, Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J. Pharm. Sci. 1992, 81, 135-140.
68. El-Gibaly, I. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. Int. J. Pharm. 2002, 249 (1), 7-21.
69. Streubel, A.; Siepmann, J.; Bodmeier, R. Floating microparticles based on low density foam powder. Int. J. Pharm. 2002, 241 (2), 279-292.
70. Struebel, A.; Siepmann, J.; Bodmeier, R. Multiple units gastroretentive drug delivery systems: a new preparation method for low density microparticles. J. Microencapsul. 2003, 20 (3), 329-347.
71. Sato, Y.; Kawashima, Y.; Takeuchi, H.; Yamamoto, H. In vivo evaluation of riboflavin-containing microbaloons for floating controlled drug delivery system in healthy human volunteers. J. Control. Release 2003, 93 (1), 39-47.
72. Atyabi, F.H.L.; Sharma, H.A.H.; Mohammed, T.J. Fell, in vivo evaluation of novel gastric retentive formulation based on ion-exchange resins. J. Control. Release 1996, 42 (2), 105-113.
73. Burton, S.; Washington, N.; Steele, R.J.C.; Musson, R.; Feely, L. Intragastric distribution of ion-exchange resins: a drug delivery system for the topical treatment of the gastric mucosa. J. Pharm. Pharmacol. 1995, 47 (11), 901-906.
74. Whitehead, L.; Fell, J.T.; Collett, J.H.; Sharma, H.L.; Smith, A.M. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J. Control. Release 1998, 55 (1), 3-12.
75. Whitehead, L.; Collett, J.H.; Fell, J.T. Amoxicillin release from a floating dosage form based on alginates. Int. J. Pharm. 2000, 270, 45-49.
76. Jackson, S.J.; Perkins, A.C. In vitro assessment of the mucoadhesion of cholestyramine to procine and human gastric mucosa. Eur. J. Pharm. Biopharm. 2001, 52 (2), 121-127.
77. Umamaheshwari, R.B.; Jain, S.; Jain, N.K. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv. 2003, 10 (3), 151-160.
78. Groning, R.; Heun, C. Oral dosage forms with controlled gastrointestinal transit. Drug Dev. Ind. Pharm. 1984, 10 (4), 527-539.
79. Cargill, R.I.; Caldwell, J.; Engle, K.J.; Fix, A.; Porter, P.A.; Gardner, C.R. Controlled gastric emptying. I. Effects of physical properties on gastric residence times of non-disintegrating geometric shapes in beagle dogs. Pharm. Res. 1988, 5 (8), 533-536.
80. Cargill, R.; Engle, K.; Gardner, C.R.; Porter, P.; Sparer, R.V.; Fix, J.A. Controlled gastric emptying. II. In vitro erosion and gastric residence times of an erodible device in beagle dogs. Pharm. Res. 1989, 6 (6), 506-509.
81. Klausner, E.A.; Lavy, E.; Stepensky, D.; Friedman, M.; Hoffman, A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm. Res. 2002, 79 (10), 1516-1523.
82. Klausner, E.A.; Eyal, S.; Lavy, E.; Friedman, M.; Hoffman, A. Novel levodopa gastroretentive dosage form: in vivo evaluation in dogs. J. Control. Release 2003, 88 (1), 117-126.